Artiam Bio

Artiam Bio is a clinical-stage biotechnology company focused on developing small molecule therapeutics for inflammatory and fibrotic diseases. The company's lead program, AB-101, is a highly selective Cannabinoid receptor 2 (CB2) agonist currently being evaluated for the treatment of Metabolic dysfunction-associated steatohepatitis (MASH). Artiam Bio's approach focuses on modulating the endocannabinoid system to provide potent anti-fibrotic and anti-inflammatory effects without the central nervous system side effects typically associated with CB1 receptor activation. Beyond MASH, the company is exploring the potential of its lead candidate in other fibrotic conditions such as systemic sclerosis and idiopathic pulmonary fibrosis. The leadership team brings extensive experience from previous successful ventures in the life sciences sector, including the founding of Spring Bank Pharmaceuticals.